Arrive AI Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARAI research report →
Range $12 – $12
Price Chart
About the company
Arrive AI Inc. operates a subscription-based "Mailbox-as-a-Service" platform. This innovative system facilitates the automated, on-demand, and secure delivery of various goods, including packages, products, and food.
- CEO
- Daniel Steven O'Toole
- IPO
- 2025
- Employees
- 41
- HQ
- Fishers, IN, US
Get TickerSpark's AI analysis on ARAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.73M
- P/E
- -0.04
- PEG
- 0.00
- P/S
- 26.31
- P/B
- 0.53
- EV/EBITDA
- -0.13
- Div Yield
- 0.00%
- Gross Margin
- -47.98%
- Op Margin
- -17214.07%
- Net Margin
- -33219.84%
- ROE
- -930.05%
- ROIC
- -318.79%
Latest fiscal year · YoY change
- Revenue
- $113.25K+0.0%
- Gross Profit
- $113.25K+0.0%
- Op Income
- $-10,253,510
- Net Income
- $-12,826,384-182.7%
- EPS
- $-19.20-166.7%
- OCF Growth
- -260.5%
- FCF Growth
- -263.9%
- 52W High
- $198.24
- 52W Low
- $0.92
- 50D MA
- $7.07
- 200D MA
- $24.80
- Beta
- 4.55
- RSI (14)
- 22
- Avg Volume
- 198.53K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Arrive AI said Q3 revenue rose to $39,700 on Hancock expansion, while management emphasized cash discipline, Nasdaq compliance actions, and a longer-term push into healthcare, defense, and robotics partnerships.· November 13, 2026
- Q3 revenue was $39,700, up from $7,450 a year ago, driven by Hancock Regional Health expanding ArrivePoints to a second building.
- Net loss improved to $3.7 million, or $3.37 per share, from $4.4 million, or $6.39 per share last year, though operating expenses rose to $3.3 million from $1.7 million.
- Management said cash and cash equivalents were $1.1 million and investments at fair value were $1 million at September 30; they also said liquidity should fund operations through the end of 2026 and into 2027.
- The company completed a 1-for-48 reverse split to address Nasdaq bid-price compliance and said the transfer to the Nasdaq Capital Market resolved two other listing deficiencies.
- Leadership highlighted new growth avenues in healthcare, specialty pharmacy, manufacturing, commercial offices, and defense, but repeatedly said several initiatives are early and have no revenue commitments yet.
Revenue for the third quarter was $39,700, consisting of $25,000 in installation fees and $14,700 in monthly subscriptions, versus $7,450 in the third quarter of last year. Net loss was $3.7 million, or $3.37 per share, compared with a net loss of $4.4 million, or $6.39 per share a year ago; per-share amounts reflect the recently announced 1-for-48 reverse stock split. Total operating expenses were $3.3 million versus $1.7 million last year. Cash and cash equivalents were $1.1 million and investments at fair value were $1 million at September 30. Management said cash and investments should fund operations through the end of 2026 and into 2027, and also said Q4 cash burn should be around $1 million per month or lower. Forward-looking commentary centered on continued limited deployments, a growing healthcare focus, and building toward a larger 2027 opportunity, with management saying it expects to be around 100 ArrivePoints in 2027.
Daniel O'Toole framed the quarter around customer expansion, especially Hancock Regional Health, which he said added a second building and helped drive revenue. He emphasized that the company is using limited deployments to learn and iterate while developing AP 4 and APX, and he repeatedly stressed discipline on spending and product standardization. His tone was upbeat but candid, mixing optimism about partnerships and 2027 with clear acknowledgment that the company remains very early and low on the revenue curve.
Piyush Phadke focused on the quarter’s financials and liquidity, citing $39,700 of revenue, $3.7 million of net loss, $3.3 million of operating expenses, and $1.1 million of cash plus $1 million of investments at September 30. He said the Q3 burn was probably a little higher than what is expected going forward, and that the goal is to run around $1 million of cash burn per month or lower, including in Q4. He also discussed the reverse split and Nasdaq transfer, noted that the split reduced shares outstanding from approximately 68.8 million to approximately 1.4 million, and said the company views the ATM as its most efficient capital-raising tool while trying to avoid excessive dilution.
Analysts pressed management on how many ArrivePoints are deployed, how quickly the 50-robot Autonomy pipeline could translate into deployments, and what recurring revenue looks like today. Management said there are 16 ArrivePoints available, deployments are intentionally limited while the company iterates new product generations, and the partnership with Autonomy is creating a unified solution they think can stand out. Questions also focused on cash burn, dilution, and the Streeterville agreement; management said cash needs are currently covered through 2026 into 2027, that the company does not anticipate needing more from Streeterville, and that future share issuance may still be part of funding growth. On the defense division, management said it was created to explore the same secure-storage-and-launch technology for military and national security markets, with foreign military sales described as potentially faster than U.S. sales cycles.
The bullish case from the call is that Arrive AI is starting to show real customer expansion, led by Hancock, while building referenceable use cases in healthcare, commercial offices, specialty pharmacy, manufacturing, and defense. Management also said it is fully funded through 2026 and into 2027, burn is being reduced, and the company expects to scale materially by 2027.
The main risks are that revenue is still extremely small, many partnerships are only at pilot or exploratory stages, and management repeatedly said several initiatives do not yet include revenue commitments. The company also needed a reverse split to stay on Nasdaq, remains dependent on capital raises, and acknowledged that dilution is likely to remain part of the story while it tries to build the business.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 52.4%
- Shares Outstanding
- 1.43M
- Float Shares
- 751.28K
of shares held by institutions
53 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aqr Capital Management LLC | 862.22K | ▲ 782.71K |
| Geode Capital Management, LLC | 155.42K | ▲ 10.13K |
| Vanguard Fiduciary Trust Co | 139.63K | 0 |
| Vanguard Capital Management LLC | 137.16K | ▲ 36.32K |
| Cygnus Capital Advisors, LLC | 117.29K | ▲ 91.29K |
| Jane Street Group, LLC | 107.27K | ▼ 180.64K |
| Vanguard Group Inc | 103.20K | ▲ 5.42K |
| Northern Trust Corp | 68.26K | ▲ 31.22K |
| Stonex Group Inc. | 59.77K | ▲ 35.44K |
| Captrust Financial Advisors | 54.68K | ▼ 12.93K |
| Tower Research Capital LLC (Trc) | 45.32K | ▲ 40.60K |
| Ieq Capital, LLC | 36.32K | ▼ 72.45K |
Held by 21 ETFs
Biggest fund positions in ARAI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 2, 26 | Fitz Michael Todd | other | 172,811 |
| Oct 2, 26 | McAdams Kevin Lewis | other | 172,811 |
| Oct 2, 26 | Gallina John E | other | 172,811 |
| Aug 17, 26 | Phadke Piyush | other | 0 |
| Aug 17, 26 | Phadke Piyush | other | 0 |
| Jul 6, 26 | Gallina John E | other | 87,413 |
| Jul 6, 26 | Fitz Michael Todd | other | 87,413 |
| Jul 6, 26 | Tucker Laurie Anne | other | 87,413 |
| Jul 6, 26 | McAdams Kevin Lewis | other | 87,413 |
| Apr 16, 26 | Fitz Michael Todd | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARAI coverage
Recent articles, reports, and earnings notes.
No research on ARAI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARAI report →Arrive AI: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 13
Arrive AI Inc. (ARAI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
Arrive AI Q3 Earnings Call Highlights
marketbeat.com · Nov 13
Arrive AI Regains Compliance with Two Nasdaq Listing Requirements with Move to the Nasdaq Capital Market and Focuses on Execution
accessnewswire.com · Oct 22
Arrive AI and Purdue University Begin Discussions on Autonomous Delivery Infrastructure Testing
accessnewswire.com · Oct 20
Arrive AI and Rivo Collaborate on Autonomous Delivery Solutions for Golf & Luxury Hospitality
accessnewswire.com · Oct 13
Arrive AI Launches Defense Division to Power the Next Generation of Autonomous Military Logistics
accessnewswire.com · Oct 12
Arrive AI Inc. (NASDAQ:ARAI) Sees Large Growth in Short Interest
defenseworld.net · Oct 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.